HMN 2025: How Genetic testing for kids with autism and mental disabilities stays uncommon in Medicaid, regardless of pointers

A brand new nationwide study reveals that almost all Medicaid-enrolled kids with autism spectrum dysfunction (ASD) or mental incapacity (ID) aren’t receiving advisable genetic testing regardless of medical pointers urging its use. The study seems within the journal Genetics in Medicine.

Researchers led by Tashalee Brown, MD, Ph.D., a post-doctoral fellow within the UCLA National Clinician Scholars Program and researcher on the Semel Institute for Neuroscience and Human Behavior at UCLA, in collaboration with colleagues at Drexel University, analyzed claims knowledge from over 240,000 kids aged 7 to 17 enrolled in Medicaid or the Children’s Health Insurance Program (CHIP) from 2008 to 2016. While testing charges had been highest amongst kids recognized with each ASD and ID (26%), charges remained surprisingly low total—simply 17% for kids with ASD alone, and 13% for these with ID solely.

“Genetic testing can provide helpful insights for prognosis and care planning,” stated Dr. Brown, the review’s lead creator. “But our findings present a significant hole between what’s advisable and what’s truly occurring in medical practice amongst kids who obtain medical insurance by way of Medicaid.”

The study additionally uncovered important racial disparities: Black kids throughout all diagnostic teams had been much less more likely to obtain genetic testing than their non-Hispanic white friends.

“Diagnosing kids with neurodevelopmental situations like autism and mental incapacity generally is a prolonged and irritating course of for households,” stated Julian Martinez, MD, Ph.D., affiliate professor of human genetics and director of the Autism Genetics Clinic at UCLA who co-led the review.

“Genetic testing supplies essential data that may finish this seek for many households, probably figuring out particular diagnoses, informing therapy approaches, and connecting households with applicable assist companies. These findings spotlight the pressing want to deal with systemic limitations that forestall equitable entry to those advisable diagnostic instruments.”

Even as newer genetic testing strategies like gene panels gained traction after 2013, the general uptake stayed restricted. The study highlights the necessity for Medicaid coverage modifications and elevated supplier training to bridge the hole between pointers and care.

“Our work underscores a well timed alternative to enhance entry to genetic testing in Medicaid,” the researchers stated. “Removing limitations may assist unlock essential diagnoses for 1000’s of youngsters with neurodevelopmental disabilities.”